How much cash does Jade Biosciences, Inc. Common Stock generate?

Jade Biosciences, Inc. Common Stock (JBIO) generated -$100.0M in operating cash flow over the trailing twelve months.

What is Jade Biosciences, Inc. Common Stock's free cash flow?

After $196.0K of capital expenditures, Jade Biosciences, Inc. Common Stock's free cash flow was -$94.9M over the trailing twelve months, down 66.7% year over year.

Where does Jade Biosciences, Inc. Common Stock's cash flow data come from?

Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Jade Biosciences, Inc. Common Stock JBIO Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$129.61M-27.0%	-$127.41M-46.4%	-$142.46M-136%	-$133.56M-109%	-$102.02M-24.1%
Depreciation and amortization	$31K-88.0%	$26K-90.8%	$25K-91.7%	$231K+112%	$258K+150%
Stock-based compensation	$24.99M+230%	$20.01M+114%	$11.87M+4.6%	$7.6M-47.8%	$7.57M-44.8%
Change in accounts payable	——	——	——	$6.53M+612%	$5.21M+460%
Change in accrued liabilities	——	——	$11.42M+526%	$7.09M+42.5%	$2.87M-53.9%
Change in other assets	——	——	——	——	——
Change in operating lease liabilities	——	——	——	——	——
Net cash from operating activities	-$100.01M-108%	-$94.69M-78.4%	-$83.65M-84.8%	-$68.33M-26.3%	-$48.17M+30.2%
Capital expenditures	——	$196K—	——	——	——
Purchases of investments	——	——	——	——	——
Proceeds from maturities/sales of investments	——	——	——	——	$64.98M-49.5%
Net cash from investing activities	-$268.33M-1,133%	-$247.01M-1,225%	-$135.72M-1,037%	$12.99M—	$25.98M—
Proceeds from issuance of common stock	$111K-99.5%	$88K-99.6%	$373K—	$351K—	$23.26M—
Net cash from financing activities	$360.67M+93.8%	$360.77M+92.7%	$282.61M+195%	$377.38M+39,458%	$186.07M+302%
Effect of exchange rate changes on cash	——	——	——	——	——
Net increase (decrease) in cash	$5.16M-96.3%	$19.05M-86.7%	$50.11M—	$308.91M—	$137.9M—
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	——	——	——
Change In Fair Value Of Convertible Notes Payable	——	$21.58M—	$34.18M—	$35.88M—	$29.7M—
Depreciation	$31K-88.0%	$26K-90.8%	$25K-91.7%	$231K+112%	$258K+150%
Increase Decrease In Accrued Expenses And Other Current Liabilities Related Parties	——	——	$2.05M—	$10.39M—	——
Accrued expenses and other liabilities	——	——	$11.42M+526%	$7.09M+42.5%	$2.87M-53.9%
Operating lease liabilities	——	——	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	$6.02M+65.3%	$11.97M+128%	$2.04M-53.4%	$1.84M-56.1%	$3.64M+60.7%
Proceeds from disposition of marketable securities and other investments	$76.24M—	$14.42M—	——	——	——
Payment Of Deferred Offering Costs	——	——	——	——	——
Accrued payables for capital expenditures	——	——	——	——	——
Value of common stock issued to settle convertible senior notes	——	$2K—	——	——	——
Deferred Offering Costs In Accounts Payable Or Accrued Expenses And Other Current Liabilities	——	——	——	——	——
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	——	——	——	——	——
Increase Decrease In Operating Lease Liability	——	——	——	——	——
Acquisitions of property and equipment included in liabilities	——	$416K—	——	——	——
Noncash Or Part Noncash Reclassification Of Warrant Liability To Equity	——	$11.14M—	——	——	——
Noncash Or Part Noncash Unpaid Offering Costs	——	$840K—	$775K—	——	——
Operating Lease Expense	——	——	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	——
Noncash Or Part Noncash Acquisition Other Liabilities Assumed1	——	$1.02M—	——	——	——
Free cash flow	——	-$94.89M—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Jade Biosciences, Inc. Common Stock generate?: Jade Biosciences, Inc. Common Stock (JBIO) generated -$100.0M in operating cash flow over the trailing twelve months.
What is Jade Biosciences, Inc. Common Stock's free cash flow?: After $196.0K of capital expenditures, Jade Biosciences, Inc. Common Stock's free cash flow was -$94.9M over the trailing twelve months, down 66.7% year over year.
Where does Jade Biosciences, Inc. Common Stock's cash flow data come from?: Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.